US Patent Issued to BIOFRONT THERAPEUTICS (BEIJING) on Aug. 11 for "Modulators of FPR1 and methods of using the same" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,703,708, issued on Aug. 11, was assigned to BIOFRONT THERAPEUTICS (BEIJING) Co. LTD. (Beijing).

"Modulators of FPR1 and methods of using the same" was invented by Tianwei Ma (Beijing), Zheng Huang (Beijing) and Feng Shi (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides at compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1)."

The patent was filed on Jan. 21, 2021, under Application No. 18/262,034.

*For further information, including images, charts and tables, please ...